Targeting the follicular lymphoma microenvironment through blockade of TNFα with etanercept

References

• Armitage J O, Weisenburger D D. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's lymphoma classification project. J Clin Oncol 1998; 16: 2780–2795
   PubMed Web of Science ®Google Scholar
• Fisher R I, LeBlanc M, Press O W, Maloney D G, Unger J M, Miller T P. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005; 23: 8447–8452
   PubMed Web of Science ®Google Scholar
• Petrasch S, Stein H, Kosco M H, Brittinger G. Follicular dendritic cells in non-Hodgkin lymphomas: localisation, characterisation and pathophysiological aspects. Eur J Cancer 1991; 27: 1052–1056
   PubMed Web of Science ®Google Scholar
• Petrasch S, Kosco M, Perez-Alvarez C, Schmitz J, Brittinger G. Proliferation of non-Hodgkin-lymphoma lymphocytes in vitro is dependent upon follicular dendritic cell interactions. Br J Haematol 1992; 80: 21–26
   PubMed Web of Science ®Google Scholar
• Lindhout E, Mevissen M L, Kwekkeboom J, Tager J M, de Groot C. Direct evidence that human follicular dendritic cells (FDC) rescue germinal centre B cells from death by apoptosis. Clin Exp Immunol 1993; 91: 330–336
   PubMed Web of Science ®Google Scholar
• Salles G, Bienvenu J, Bastion Y, Barbier Y, Doche C, Warzocha K, et al. Elevated circulating levels of TNFα and its p55 soluble receptor are associated with an adverse prognosis in lymphoma patients. Br J Haematol 1996; 93: 352–359
   PubMed Web of Science ®Google Scholar
• Gruss H J, Dower S K. Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas. Blood 1995; 85: 3378–3404
   PubMed Web of Science ®Google Scholar
• Culy C R, Keating G M. Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis. Drugs 2002; 62: 2493–2537
   PubMed Web of Science ®Google Scholar
• Harris N L, Jaffe E S, Diebold J, Flandrin G, Muller-Hermelink H K, Vardiman J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17: 3835–3849
   PubMed Web of Science ®Google Scholar
• Cheson B D, Horning S J, Coiffier B, Shipp M A, Fisher R I, Connors J M, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244
   PubMed Web of Science ®Google Scholar
• Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma A A, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999; 35: 1773–1782
   PubMed Web of Science ®Google Scholar
• Husson H, Lugli S M, Ghia P, Cardoso A, Roth A, Brohmi K, et al. Functional effects of TNF and lymphotoxin α1β2 on FDC-like cells. Cell Immunol 2000; 203: 134–143
   PubMed Web of Science ®Google Scholar
• Friedberg J W, Fischman A, Neuberg D, Kim H, Takvorian T, Ng A K, et al. FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: a blinded comparison. Leuk Lymphoma 2004; 45: 85–92
   PubMed Web of Science ®Google Scholar
• Lee A M, Clear A J, Calaminici M, Davies A J, Jordan S, MacDougall F, et al. Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J Clin Oncol 2006; 24: 5052–5059
   PubMed Web of Science ®Google Scholar
• Hilchey S P, De A, Rimsza L M, Bankert R B, Bernstein S H. Follicular lymphoma intratumoral CD4+CD25+GITR+ regulatory T cells potently suppress CD3/CD28-costimulated autologous and allogeneic CD8+CD25− and CD4+CD25− T Cells. J Immunol 2007; 178: 4051–4061
   PubMed Web of Science ®Google Scholar
• Dave S S, Wright G, Tan B, Rosenwald A, Gascoyne R D, Chan W C, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004; 351: 2159–2169
   PubMed Web of Science ®Google Scholar
• Johnson P W, Watt S M, Betts D R, Davies D, Jordan S, Norton A J, et al. Isolated follicular lymphoma cells are resistant to apoptosis and can be grown in vitro in the CD40/stromal cell system. Blood 1993; 82: 1848–1857
   PubMed Web of Science ®Google Scholar
• Freedman A S, Munro J M, Rice G E, Bevilacqua M P, Morimoto C, McIntyre B W, et al. Adhesion of human B cells to germinal centers in vitro involves VLA-4 and INCAM-110. Science 1990; 249: 1030–1033
   PubMed Web of Science ®Google Scholar
• Anolik J H, Ravikumar R, Barnard J, Owen T, Almudevar A, Milner E C, et al. Cutting edge: anti-tumor necrosis factor therapy in rheumatoid arthritis inhibits memory B lymphocytes via effects on lymphoid germinal centers and follicular dendritic cell networks. J Immunol 2008; 180: 688–692
   PubMed Web of Science ®Google Scholar
• Ott K, Weber W A, Lordick F, Becker K, Busch R, Herrmann K, et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 2006; 24: 4692–4698
   PubMed Web of Science ®Google Scholar
• Wieder H A, Brucher B L, Zimmermann F, Becker K, Lordick F, Beer A, et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 2004; 22: 900–908
   PubMed Web of Science ®Google Scholar
• Brown S L, Greene M H, Gershon S K, Edwards E T, Braun M M. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002; 46: 3151–3158
   PubMed Web of Science ®Google Scholar
• Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004; 50: 1740–1751
   PubMed Web of Science ®Google Scholar
• Geborek P, Bladstrom A, Turesson C, Gulfe A, Petersson I F, Saxne T, et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 2005; 64: 699–703
   PubMed Web of Science ®Google Scholar
• Hochberg M C, Lebwohl M G, Plevy S E, Hobbs K F, Yocum D E. The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. Semin Arthritis Rheum 2005; 34: 819–836
   PubMed Web of Science ®Google Scholar
• Tsimberidou A M, Giles F J, Duvic M, Kurzrock R. Pilot study of etanercept in patients with relapsed cutaneous T-cell lymphomas. J Am Acad Dermatol 2004; 51: 200–204
   PubMed Web of Science ®Google Scholar
• Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 2006; 28: 1779–1802
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry M C, Brahmer J, Schiller J H, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542–2550
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335–2342
   PubMed Web of Science ®Google Scholar
• Yang J C, Haworth L, Sherry R M, Hwu P, Schwartzentruber D J, Topalian S L, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427–434
   PubMed Web of Science ®Google Scholar